maged elshamy

Prof. maged elshamy


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
MEmaged elshamy
maged elshamy
AAAmien I. Ahmed
Amien I. Ahmed
An open access, peer-reviewed, online scientific research journal focused on global health

1 January 2020 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
IAIbrahim Albahlol
Ibrahim Albahlol
MEmaged elshamy
maged elshamy
HEHany El-Hady
Hany El-Hady
EAEl-Sayed Mahmoud Abd-Elwahab
El-Sayed Mahmoud Abd-Elwahab

1 March 2024 in The Egyptian Journal of Fertility and Sterility
Verified
Journal Article
Open access
PDF file
QSQouttah Abd El-Salam Shoshan
Qouttah Abd El-Salam Shoshan
MEmaged elshamy
maged elshamy
AWAlaa Wageh
Alaa Wageh
MTMahmoud Thabet
Mahmoud Thabet
Ethical statement Authors declare that there is no interestNo fund.Accepted by the Ethical Research Committee of the Obstetrics and Gynecology Department and institutional review board (IRB) in the Faulty of Medicine (MS.21.12.1763)Written informed consent was taken from the participants Introductionan urgent need for new medication without impeding the patient’s fertility. cabergoline, Metformin, and Clomiphene citrate have been studied in experimental model in cases of endometriosis. however, there was still no evidence of its use with mild endometriosis. Our study’s goal was to see if use these medications could help women with minimal to mild endometriosis. MethodsBetween November 2021 to November 2022, 150 Infertile women with minimal to mild endometriosis were recruited from outpatient Gynecology clinic for this study a prospective, randomized trial.The cases will be randomly assigned to receive one of the four treatment modalities by using computer generate random table and sealed envelop Group A: they got cabergoline (0.25 mg twice weekly) for three months. Group B: they received metformin 500 mg three times daily for three months. Group C: they received Clomiphene citrate (50mg twice daily for 5days) from second day of menstrual cycle for three months. Group D: they got placebo once per day during the three months follow up period Serum prolactin (PRL), basal follicular stimulating hormone (FSH), basal luteinizing hormone (LH), basal serum estradiol (E2) and midluteal serum progesterone (P) were measured before the start of the treatment.After the three months, a clinical evaluation was conducted, which compromised clinical examination with assessment of dysmenorrhea, dyspareunia and pelvic pain, menorrhagia, and pregnancy. A second hormonal assessment was performed. ResultsFor group A; 20 cases, for group B 22 cases, for group C 20 cases, and for group D 17 cases were analyzed. The mean prolactin level, mean FSH level, and mean estradiol level after treatment statistically significant difference between studied group and placebo. The pregnancy in studied groups were 8 out of 20 in Group A, 10 out of 22 in Group B, 8 out 20 in Group C, however, 2 out of 17. ConclusionWe had encouraging results from the use of cabergoline, metformin, and clomiphene citrate in patient with mild to moderate endometriosis.